SS Innovations International (NASDAQ: SSII) CEO Outlines Growth Strategy as SSi Mantra Expands Robotic Surgery, Telesurgery, and Global Reach

At a glance

Company: SS Innovations International
Ticker: NASDAQ: SSII
Announcement: Expansion

Key figures

Procedures using robotic systems: more than 15,000
Cardiac procedures using robotic systems: approximately 750
Telesurgeries using the platform: more than 200
Cardiac telesurgeries: 27
Planned Indian manufacturing facility: 10-acre
First-half 2026 revenue: about $25 million

People

Dr. Sudhir SrivastavaCEO

Products and programs

SSi Mantra robotic surgical platform

CEO Dr. Sudhir Srivastava, in a recent interview with The Motley Fool , that SS Innovations has performed more than 15,000 procedures using its SSi Mantra robotic surgical systems, including approximately 750 cardiac procedures.
In addition, more than 200 telesurgeries have been performed using the platform, including 27 cardiac procedures, as the company explores ways to extend specialist surgical expertise to underserved communities.
Srivastava highlighted the SSi Mantra’s differentiated engineering, including its 4K 3D visualization, surgeon-controlled anatomical imaging and modular design supporting up to five robotic arms.
SS Innovations is preparing to expand its Indian manufacturing capacity through a planned 10-acre facility, with the objective of bringing additional production capabilities in-house.
Regulatory applications in Europe and the United States are also progressing, with management targeting international expansion through direct sales and opportunities in ambulatory surgery centers.
The company is experiencing strong commercial momentum, with first-half 2026 revenue increasing approximately 66% year-over-year to about $25 million.

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, is seeing increased adoption of its SSi Mantra surgical robotic platform, with CEO Dr. Sudhir Srivastava telling The Motley Fool’s interviewer Rachel Warren that the company’s commercial growth reflects a combination of technological capabilities, clinical experience and affordability (https://ibn.fm/EJk05).

During the interview, Srivastava said the company had performed more than 15,000 procedures using its robotic systems, including approximately 750 cardiac surgeries. He also highlighted the platform’s expanding use across multiple…

Questions around this news

What capabilities does the SSi Mantra robotic surgical platform offer?
The release describes the platform as offering 4K 3D visualization, surgeon-controlled anatomical imaging and a modular configuration that can support up to five robotic arms. It also reports use of the system in more than 15,000 procedures, including approximately 750 cardiac procedures.
How is telesurgery being used with the SSi Mantra platform?
The release says more than 200 telesurgeries have been completed using the platform, including 27 cardiac procedures. The company is exploring telesurgery as a way to extend specialist surgical expertise to underserved communities.
What expansion plans did SS Innovations describe?
The company is preparing to expand its manufacturing capacity in India with a planned 10-acre facility intended to bring additional production capabilities in-house. It is also pursuing regulatory applications in Europe and the United States, and management described plans for international growth through direct sales and opportunities in ambulatory surgery centers.

SEC filings

Earlier from SS Innovations International

Back to News Center

SS Innovations International (NASDAQ: SSII) CEO Outlines Growth Strategy as SSi Mantra Expands Robotic Surgery, Telesurgery, and Global Reach